The Notice · CMS‑3487‑NC · August 2026

Medicare coverage, the same day the FDA clears the device.

For decades a cleared device waited a year or more for a national coverage decision — the “reimbursement valley of death.” CMS’s new RAPID pathway collapses it: a proposed national coverage decision the same day as FDA market authorization, and coverage possible in as little as 60 days. The catch is not the speed. It’s where the work moved.

The facts, dated. CMS and FDA announced RAPID on April 23, 2026. The procedural notice — CMS‑3487‑NC — reaches the Federal Register on August 11, 2026, opening a 60‑day comment window. It covers FDA Breakthrough devices only; in‑vitro diagnostics are excluded; and coverage still is not automatic.

What it actually changes

It doesn’t make the paperwork faster. It moves the coverage decision upstream — into the trial.

The old model treated FDA clearance and Medicare coverage as two disconnected events, run in sequence, by two agencies that never compared notes until the device was already on the market. RAPID stitches them together before the first patient is enrolled. The mechanism is three moves:

Before the study

Align the endpoints with both agencies.

Manufacturer, FDA, and CMS agree up front on the clinical outcomes that matter to the Medicare population — how a patient feels, functions, or survives — not just the safety-and-efficacy endpoints FDA needs to clear a device.

During the study

Build the Medicare evidence into the IDE trial.

The investigational study carries those agreed endpoints from day one. In practice that means more Medicare-age beneficiaries, more outcome-based endpoints, and longer follow-up than a trial designed for FDA clearance alone.

At authorization

A proposed coverage decision the same day.

When the FDA authorizes the device, CMS posts a proposed national coverage determination that day. After a comment period, national coverage can follow in as little as 60 days — against the year-plus it takes today.

You can no longer earn coverage after the fact. You either designed the proof in, or you didn’t.

The part worth reading twice

RAPID doesn’t reward the fastest device. It rewards the one that can prove the outcome CMS pays for.

Strip away the acronym and this is a statement about what counts as evidence. Coverage no longer follows the claim; it follows the outcome you captured — in real Medicare patients, over real follow-up, measured as function and survival rather than a device spec. Analysts reading the same notice put it plainly: the trials that qualify will be more robust, with more patient-outcomes-based endpoints and longer follow-up than most studies built for FDA authorization alone. The reward is predictable coverage. The price is a harder, longer, more honest study.

That is the whole argument I have been making, now written into federal coverage policy: in the system that’s coming, the asset is the provable outcome — captured, attributed to the population that matters, and standing up to a payer’s scrutiny. The model that generates a device, and the software that files a claim, are commodities. The evidence that a real person got better, and that someone credible stands behind it, is not.

And for the higher-risk devices, the proof never stops. RAPID can grant coverage with evidence development — a conditional yes that keeps requiring real-world outcomes in Medicare patients until the case is closed. That turns the outcome record from a one-time trial artifact into a standing obligation: continuous, longitudinal, and owned by whoever sits closest to the patient. The one-time study proves the device; the ongoing record is what keeps it covered.

Coverage is becoming downstream of proof. Whoever owns the proof owns the coverage.

Who should feel this

Device makers — especially in orthopedics.You can no longer design a trial for FDA safety and efficacy and sort out reimbursement later. If you want the 60-day coverage window, the Medicare-population outcomes — function, comorbid patients, longer follow-up — have to be in the protocol from the start. The functional-outcome capture that used to be a nice-to-have is now the gate.

Everyone building the outcome layer.RAPID is a device pathway — pure software and diagnostics sit outside it, and I want to be precise about that. But it validates the currency the rest of my work mints: the attested, patient-reported, real-world functional outcome. RAPID makes it the price of fast coverage for devices; the same evidence is what turns care into something a payer will pay for everywhere else.

Innovators who missed the window.Entry is at the pre-submission stage. Devices already authorized, or mid-study, are outside the fast lane for now — CMS is asking whether to build a bridge for active trials. Upstream regulatory architecture just became a first-order design decision, not an afterthought.

The notice is about devices. The lesson is about all of it: coverage now follows the outcome you can prove — and the outcome you can prove is the one a named human captured and stands behind.

That’s the layer I’m building across the journey — the human-signed, owned record that remembers and answers to someone. Read the fuller thesis →

Blaine Warkentine, MD · SolvingHealth · Boulder, CO · Get in touch →

Primary sources

Analysis of a public federal notice for general information — not legal, regulatory, or reimbursement advice. Timeline figures (same-day proposed NCD; coverage possible in ~60 days; 60-day comment period) are drawn from the CMS and FDA sources above and reflect the pathway as proposed; final terms follow the comment period.